January 15, 2020 06:35 AM EST
FDA+

UK's NICE is­n't con­vinced by Mer­ck­'s Keytru­da in head and neck can­cer

Natalie Grover

Reporter

There may be 33 new cas­es of head and neck can­cer in the Unit­ed King­dom each day, but the re­gion’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times